<span style="font-size: 20.5pt;mso-bidi-font-size:13.5pt;font-family:"Times New Roman","serif"">Fatty acids derived from a marine crustacean <i><span style="font-size:21.0pt; mso-bidi-font-size:14.0pt;font-family:"Times New Roman","serif"">Diogenes avarus </span></i><span style="font-size:20.5pt;mso-bidi-font-size:13.5pt; font-family:"Times New Roman","serif"">(Heller) and their antiangiogenic activity </span></span>

Abstract

632-635<span style="font-size: 15.5pt;mso-bidi-font-size:8.5pt;font-family:" times="" new="" roman","serif""="">An organic extract from a marine crustacean <span style="font-size:15.0pt; mso-bidi-font-size:8.0pt;font-family:" arial","sans-serif""="">D. avarus <span style="font-size:15.5pt;mso-bidi-font-size:8.5pt;font-family: " times="" new="" roman","serif""="">was examined for antiangiogenic activity by using the chick embryo chorioallantoic membrane (CAM) assay. The methanol extract (HCM) inhibited angiogenesis in a dose dependent manner. The extract was further fractionated by bioactivity-guided separation to purify the active fractions successively. This resulted in three fractions HCM1, HCM2 and HCM3. The 50% inhibition shown by HCM was 600ng/disc, HCM 1 was <span style="font-size: 15.5pt;mso-bidi-font-size:8.5pt;font-family:" times="" new="" roman","serif""="">100ng/disc and of HCM3 was 2.7ng/disc. HCM3 which was separated by column chromatography and showed single spot on TLC was analysed by GLC and showed the presence of saturated and unsaturated fatty acids such as lauric, myristic, palmitic, stearic, oleic, linoleic. The antiangiogenic activity of the fatty acids obtained from a marine crustacean is reported <span style="font-size:15.5pt;mso-bidi-font-size:8.5pt;line-height:115%; font-family:" times="" new="" roman","serif";mso-fareast-font-family:"times="" roman";="" mso-ansi-language:en-us;mso-fareast-language:en-us;mso-bidi-language:ar-sa"="">for the first time.</span